Large gap with delayed quotes
|
Last quote
12/26/2024 -
20:00:00
|
Bid
12/27/2024 -
07:00:06
|
Bid Volume |
Ask
12/27/2024 -
07:00:06
|
Ask Volume |
|---|---|---|---|---|
|
32.955
-0.365
(
-1.10% )
|
32.01
|
100 |
38.15
|
100 |
Analysis date: 24.12.2024
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 11.10.2024.
Interest
Strong
Strong
Strong interest since 22.11.2024.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 05.11.2024 at a price of 28.07.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, at its current price the stock is moderately undervalued.
MT Tech Trend
Positive
Positive
The forty day Medium Term Technical Trend is positive since 22.11.2024. The confirmed Technical Reverse point (Tech Reverse - 1.75%) is 31.269.
4wk Rel Perf
3.54%
3.54%
The four week relative overperformance versus SP500 is 3.54%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 11.10.2024.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 0.99%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.47%.
Mkt Cap in $bn
4.13
4.13
With a market capitalization between $2 & $8bn, APELLIS PHARMS. is considered a mid-cap stock.
G/PE Ratio
2.12
2.12
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
36.67
36.67
The estimated PE is for the year 2027.
LT Growth
77.90%
77.90%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
17
17
Over the last seven weeks, an average of 17 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
105
105
For 1% of index variation, the stock varies on average by 1.05%.
Correlation
0.27
0.27
Stock movements are strongly independent of index variations.
Value at Risk
15.42
15.42
The value at risk is estimated at USD 15.42. The risk is therefore 46.26%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
22.04.2022
22.04.2022